C O N F I D E N T I A L | www.azurrx.com
CORPORATEPRESENTATION
(NASDAQ:AZRX)
January2018
2
Certainstatementsinthispresentationconstitute“forward-lookingstatements”withinthemeaningofSection21EoftheSecuritiesExchangeActof1934,asamended.Anystatementsthatrefertoexpectationsorothercharacterizationsoffutureevents,circumstancesorresultsareforward-lookingstatements.Suchforward-lookingstatementsincludeprojections.SuchprojectionswerenotpreparedinaccordancewithpublicguidelinesoftheAmericanInstituteofCertifiedPublicAccountantsregardingprojectionsandforecasts,norhavesuchprojectionsbeenaudited,examinedorotherwisereviewedbyindependentauditorsofthecompany.Suchforward-lookingstatementsinvolveknownandunknownrisks,uncertaintiesandotherfactorswhichmaycausetheactualresults,performanceorachievementsofthecompanytobemateriallydifferentfromanyfutureresults,performanceorachievementsexpressedorimpliedbysuchforward-lookingstatements.
Theviewsexpressedarethoseofmanagementandarebasedoncurrentlyavailableinformation.Estimatesandprojectionscontainedhereinhavebeenpreparedbymanagementandinvolvesignificantelementsofsubjectivejudgmentandanalysisandarebasedoncertainassumptions.Norepresentationnorwarranty,expressedorimplied,ismadeastotheaccuracyorcompletenessoftheinformationcontainedinthisdocument,andnothingcontainedhereinis,orshallbereliedupon,asapromiseorrepresentation,whetherastothepastorthefuture.Theprojectionsarenotintendedtofollowgenerallyacceptedaccountingprinciples.Neitherouraccountantsnorourlegalcounselhavecompiled,audited,prepared,orcontributedtotheprojectionsortheunderlyingassumptions.Noneofthesepartiesexpressanopinionwithrespecttotheprojections.
Youarecautionednottoplaceunduerelianceontheseforward-lookingstatements.Exceptforongoingobligationsofthecompanytodisclosematerialinformationunderthefederalsecuritieslaws,thecompanydoesnotundertakeanyobligationtoreleaseanyrevisionstoanyforward-lookingstatements,toreporteventsortoreporttheoccurrenceofunanticipatedevents.
CompanyDisclaimer
© AzurRx BioPharma < www.azurrx.com <
3
§ Biotechnologycompanyfocusedonthedevelopmentoftherapeuticproteins
§MultiplepipelineprojectsaddressinglargeglobalmarketsinGIandinfectiousdiseases
§MS1819fortreatmentofExocrinePancreaticInsufficiency(EPI)inpatientswithChronicPancreatitis(CP)andCysticFibrosis(CF)
– ClinicalproofofconceptforCPdemonstratedinFLIP-110study
– PreliminaryPhase2datasupportsefficacyandsafetyinCP
– Large,immediatelyaddressableEPImarketof~$1BinU.S.,$1.5Bworldwide(1)
– PartneredwithMayoly-SpindlerinEuropecovering30%ofMS1819clinicalcosts
§AZX1101betalactamasesForpreventionofnosocomial(hospitalacquired)andC.difficileinfectionsinpreclinicaltesting
– Addressesa$4.5-$11billionmedicalissue(2)
§Highlycashefficientoperationswith~30%ofR&DspendrebatedbyFrenchgovernment
(1) U.S.marketsize.Abbvie 2013-201710-Ksandannualreports(Creon),Zenpep &Pancreaze basedon2013-2014IMShistoricaldata/analystprojection.ManagementestimatesforglobalEPImarketsize
(2) CDC2016 © AzurRx BioPharma < www.azurrx.com <
InvestmentHighlights
4
Product Description IndicationDevelopmentPhase
Discovery Pre-Clinical Phase1 Phase 2 Phase3
MS1819
Yeastrecombinantlipase (Yarrowialipolytica LIP2)
TreatmentofEPI inCPpatients
TreatmentofEPI inCFpatients(1)
AZX1101 Synthetic β-Lactamase
Prevention ofnosocomialinfectionsandantibioticassociateddiarrhea
Expectedprogressin2018CurrentStatus
GITherapeuticProductPipelineMS1819
(1) Phase1carriedoutinEPIpatientswithCP
5
§ Pancreasfunctioncanbecompromisedduetopancreaticcancer,surgicalexcisionorbehavioralissues(i.e.alcoholism),etc.
TherearetwobroadpatientspopulationswhichsufferfromEPIandrequiretreatment
CysticFibrosis(~30,000patients)
ChronicPancreatitis(~90,000patients)
§ Diseaseisgeneticandmajorityofpatientsrequiretreatmentfromage4onwards
ExocrinePancreaticInsufficiency(EPI)EPIisaconditioncharacterizedbydeficiencyofpancreaticenzymes,resultingintheinabilitytodigestfoodproperly
6
FoodDigestionNeedsEnzymes,FatNeedsaLipaseAmylasesandproteasesinsalivaandstomachcompensateinpancreaticinsufficiency,butnobackupexistsforfatdigestion
Fat Fattyacids&glycerol
Protein Aminoacids
Carbohydrate Glucose
Amylase
Protease
Lipase
Ifthepancreasdoesnotfunctionproperly,oralsupplementsaretakentoallowforfatdigestion
7
ClearUnmetMedicalNeed
CurrentEPITreatmentLimitations
§ Limitedeffectiveness
§ Lackofstabilityinacidicenvironment
§ Highpillburden
– Inconvenientforpatients
– Non-adherence
§ Sourcingandsupplyofporcine-derivedpancrelipase(PPEs):
– Subjecttopigherdmanagement
– Riskoftransmissionofpathogens
– Manufacturing/supplychaininconsistency
§ Adverseevent:fibrosingcolonopathy athighdoses
Opportunity§ Abilitytoreducepatientdailypillburdenof~25-40capsulesdownto~5-8 DailyDose
StandardofCare(1)
ExpectedDailyDoseMS1819
vs.
MS1819Current
(1) StandardofcareincludesdrugssuchasCreon,Zenpap andPancreaze
8
Large Established US Market Of ~$1.1 Billion(1)
All lipase products are pig derived and are less active at the pH in humans resulting in a large pill burden
(1) U.S.marketsize.Abbvie2013-201710K’s,10Q’sandannualreports(Creon),Zenpep&Pancreaze&Pertyzebasedon2013-2016 IMShistoricaldata/analystprojection(2) Creon2013-2016A- Abbvie,2017-2021E(3) 2017-2021EZenpepbasedonmedianorequityresearchprojections(4) 2021Pancreaze&Pertyzeequityresearchprojectionsunavailable
Growth, % 2014 2015 2016 2017 2018 2019 2020 2021
Creon(Abbvie)(2) 25.2% 22.5% 15.5% 11.1.% 6.6% 6.0% 4.5% 5.9%
Zenpep(Allergan)(3) - 105.4% 20.4% 6.5% 3.3% 3.2% 3.1% 11.3%
Pancreaze(J&J)(4) 4.0% 5.0% 2.4% -6.7% 4.7% 5.0% 5.1% -
Pertyze(Cornerstone)(4) - - 60.0% 42.3% 27.7% 18.0% 9.0% -
412 516632 730 811 865 917 958 1,015
3738
4042
4446 49 50
72
167201
214221
228 235 262
2013A 2014A 2015A 2016A 2017E 2018E 2019E 2020E 2021E
Historical Projected
$inmillions
1,207 1,259 1,277
1,076980
633
455
1,143
844
9
In-Vitro ActivityofMS1819atpHRange
InvitrolipolyticactivityoftheMS1819lipaseinthepresenceofbilesaltsintheEuropeanandUSPharmacopeiatest(U/mg,PureEnzyme)
8
Lipo
lytic
Activ
ity(U
/mgofpurified
enzymeeq
uivalent)
14,000
12,000
10,000
8,000
4,000
2,000
6,000
NormalpH
PathologicalpH
9 7 5 4 36
MS1819Lipaseshowssuperioractivitytoporcinelipase
standardofcareattherelevantintestinalpH
range
MS1819 PorcinePancreaticExtract
0
Note:Innormalsubjects,physiologicalpHinduodenumisbetweenapproximately5and6.InCPandCFpHisloweredtoamore acidicrange,approximatelypH4to5.MS1819notinactivatedbybilesalts.
pHBasic Acidic
10
Steatorrhea,PerProtocol(absolutedifference12.6%)
CoefficientofFatAbsorption(CFA)**,PerProtocol(absolutedifference16.2%)
CFA(%)Steatorrhea(g/day)
40.3
31.539.6
44.1
01020304050607080
Baseline Treatment
MS1819 Placebo
49.659.18
48.9542.3
01020304050607080
Baseline Treatment
MS1819 Placebo
FLIP110StudyPerProtocolEfficacyResults(1)MS1819suggestsimprovementoftwokeyefficacyparameters
(1) Studynotpoweredforstatisticalsignificance,Pilot,proofofconceptstudy;mainobjectiveofsafetywithexplorationofefficacy**CFA=coefficientoffatabsorption,ameasureofdietaryfatdigestion
Resultsobtainedonthe2mainefficacycriteria(steatorrheaandCFA)demonstratedapositiveeffectofMS1819comparedtoanegativeeffectofthe
placebo.
11
ClinicalTrialDesignforMS1819Phase2ainChronicPancreatitisTrialstartedinQ42016inAustraliaandNewZealand;12-15patientsenrollmenttarget
(B)Washout12-15days
(C)Open-labelphase
12-15dayseachstep
(A)Screening0-30days
UsualPPEtreatment
PreviousPPEtreatment
Screening
MS1819-SD2240mg/day
Baseline
Inclusion
MS1819-SD280mg/day
MS1819-SD560mg/day
MS1819-SD1120mg/day
(D)Follow-up12-15days
V1 V2 V3
V4
V5
V6 V7
V8
Fecalelastase-1atscreening<100µg/gInpatientCFAmeasurement(meanof3consecutivedays)OutpatientCFAmeasurement(meanof3consecutivedays)
12
0
5
10
15
20
25
30
CFAImprovement
Porcine MS1819Ph1a/b
Bacteriallipase
Abso
lute
% In
crea
se F
rom
Was
hout
Doseresponse MS1819highestdoseshows>21%CFAimprovement
Clinicalactivity Response inverselycorrelatedtodiseaseseverity
Bristolscale Improvement
Nutritionalstatus Favorable(unchanged)
Peakresponse 57%CFAImprovement
Safety Noseriousadverseeventsornotablemildtomoderateevents
DatafromMS1819highestdose
MS1819CFAResponseInitialresultsdemonstratedCoefficientofFatAbsorption(CFA)improvement,solidsafetyprofile,anddoseresponse
13
PerProtocol– CFAAbsolute(%)
PerProtocol– RelativeCFAchange(%)
MS1819Phase2aResultsareFavorableFirst6patients’resultsshowCFAimprovement,solidsafetyprofile,anddoseresponse
48.4%55.5%
61.0%68.8% 69.8%
WO 280mg/d 560mg/d 1120mg/d 2240mg/d
-
7.1%
12.6%
20.4% 21.4%
WO 280mg/d 560mg/d 1120mg/d 2240mg/d
14
PCT/FR1999/002079 family PCT/FR2000/001148 family PCT/FR2006/001352 familyTitle Methodfornon-homologous
transformationofYarrowialipolytica
Cloningandexpressinganacid-resistantextracellularlipaseofYarrowia lipolytica
Methodforproducinglipase,transformedYarrowialipolyticacellcapableofproducingsaidlipaseandtheiruses
Abstract TheinventionconcernstheintegrationofageneofinterestintothegenomeofaYarrowia straindevoidofzetasequences,bytransformingsaidstrainusingavectorbearingzetasequences
Theinventionconcernsnucleicacidscodingforacid-resistantextracellularlipases,inparticularC.ernobiiorYarrowialipolyticayeastsandtheproductionofsaidlipasesinrecombinantform
MethodforproducingYarrowialipolyticaacid-resistantrecombinantlipaseutilizingaculturemediumwithoutanyproductsofanimaloriginornon-characterizedmixturessuchastryptone,peptoneorlactoserum,inadditiontoitsuses
Prioritydate 01.09.1998(FR98/10900) 28.04.2000(FR00/01148) 15.06.2006(F026900039)
§ MS1819coveredbygrantedpatentsuptoJune15th,2026(1)
§ ApatenttermextensionofuptofiveyearsmaybegrantedbytheUSPTO,resultinginpossibleendoftheprotectiononJune15th,2031(1)
§ TheFDAcurrentlygrants12yearsofexclusivityfornovelbiologicsfromfirstapproval(e.g.through2033ifapprovedin2021)
§ Freedomtooperate:noblockingpatentshavebeenidentifiedsofar
.
IntellectualPropertyLicensedpatentsrelativetotheMS1819program
(1) RelatestoPCT/FR2006/001352family
15
Competition to date
Approved and marketed – Only PPEs1 – A mix of lipase, protease and amylase
a.CREON®, Abbott
b.ZENPEP®, VIOKASE® and ULTRESA®, Aptalis Pharma
c.PANCREAZE®, Johnson and Johnson
d.PERTZYE®, Digestive Care Inc.
Recombinant products under development for EPI
a.SOLPURA® aka Liprotamase®, Alnara/Eli Lilly (cross-linked bacterial lipase, protease and amylase)
b.NM-BL burlulipase, Nordmark Pharma (bacterial lipase)
1 All PPE’s must go through NDA approval since 4/28/2004 announcement by FDA
Terminated recombinant products for EPI
a.Dog recombinant lipase, rGL, Meristem
b.Recombinant Microbial Lipase, SLV-339, Solvay Pharmaceuticals
c.Human bile-salt stimulated lipase (rhBSSL), Biovitrum AB-for neonates
16
ExocrinePancreaticInsufficiencyPrimaryMarketResearchSupportforMS1819fromPhysiciansandPayers(1)
(1) Resultsof10gastroenterologistand5payerinterviewsconductedbyanoutsideresearchfirmin8/2014
87%ofalldiagnosedEPIpatientsaretreatedwithpancreaticenzymereplacementtherapy
Reducingpillburden,increasingpHstability,andprovidingaporcinealternativePancreaticEnzymeReplacementTherapies(PERTs)isseenasasignificantopportunityinmeetingcurrentunmetneeds
PotentialforMS1819tocapture57%ofnewlydiagnosedEPIpatients;howeverthereislikelylimitedswitchingopportunityforcurrentlytreatedpatients
InterviewedpayersdonotactivelymanagecostsacrossPERTs,whiletheyhaveapositiveviewofMS1819,theydonotfeelthattherearegroundsforhigherpriceswithoutmoreclinicaldata
17
Product Description IndicationDevelopmentPhase
Discovery Pre-Clinical Phase1 Phase 2 Phase3
MS1819
Yeastrecombinantlipase (Yarrowialipolytica LIP2)
TreatmentofEPI inCPpatients
TreatmentofEPI inCFpatients(1)
AZX1101 Synthetic β-Lactamase
Prevention ofnosocomialinfectionsandantibioticassociateddiarrhea
Expectedprogressin2018CurrentStatus
GITherapeuticProductPipelineAZX1101
(1) Phase1carriedoutinEPIpatientswithCP
18
Mostmodernantibioticskillbothgoodandbadmicrobes,strippingthebodyoffriendlybacteriaintheprocessofadministration
Bothfriendlyandharmful organismsexistnaturally
Theymayunintentionallyupsetthenaturalbalanceofthegutmicrobiomebykillingoffgoodbacteria
Microbeslivingonandwithinthehumanbody
Deathofmicrobes– Badlefttoflourish
IVantibioticsarecarriedtotheliver,transportedtobileandexcretedviathelargeintestine
Antibiotics
TheMicrobiomeandDiseaseTheImpactofModernAntibiotics
19
14MPatients
27MPrescriptions
80-400MDoses
$2B-10BMarket
• PatientsrequiringIVantibiotictherapy
• Higherriskpatientswithmultiplescripts
• 15-75%market
• 5daysprescriptiontherapy
• 4Dosesperday
• $25perdose
ScaleoftheC.DiffProblemand14MPatientsAffectedAnnually(1)AZX1101forthePreventionofC.DifficileInfectionsandNosocomialInfections
(1) Sources:2012IMSHealthandCDMHospitaldatabases.Managementestimates.
20
§ Applications
– Oral,non-systemicmedicinetoactlocallyintheGItractwiththepotentialtopreventhospital-acquiredinfectionsbyresistantbacterialstrainsinducedbyparenteraladministrationofβ-lactamantibiotics.
– Potentialpreventionofantibiotic-associateddiarrhea(AAD).
§ Hospital-acquired(nosocomial)infectionshaveahugeeconomicimpactonsociety(2) andareamajorpublichealthconcerncontributingtoincreasedmorbidity,mortality,andcost.
– TheCentersforDiseaseControl(CDC)hasestimatedthatroughly1.7millionhospital-associatedinfections(i.e.~5%ofthenumberofhospitalizedpatients),causeorcontributeto99,000deathseachyearintheUSA(1),withtheannualcostrangingfromUS$4.5to$11billion).
§ TheCentersforMedicareandMedicaidServices(CMS)hasbeguntopenalizehospitalsbynotpayingfor“avoidablecosts.”
AZX1101– OpportunityOverviewAddressingNosocomialInfections
(1) CDC2016.Managementestimates.(2) ~2million(HAIs)intheU.S,90,000estimateddeaths.CentersforDiseaseControl.2016OveralldirectcostofHAIstohospitalsrangesfrom$28-$45B.Scott,R.Douglas.
”TheDirectMedicalCostsofHealthcare-AssociatedInfectionsinU.S.HospitalsandtheBenefitsofPrevention”.CentersforDiseaseControlandPrevention.March2009.
21
AZ1101Penicillins(withoutbetalactamaseinhibitors)
Penicillins(withbetalactamaseinhibitors)
3rd generation cephalosporins
Methicillin
Aminoglycosides
Somefluoroquinolones
Macrolides
Tetracyclines
Lincosamides
AZX1101TargetsMultipleAntibioticsintheGutFiledIntellectualPropertyCoversMultipleAntibioticClasses
22
ManagementTeam
ThijsSpoorCEO
Maged ShenoudaCFO
DanielDupretChiefScientificOfficer
YvesLeblondDirectorResearchandDevelopment
LucLebretonR&DProgramsDirector
MartinKrusinBusinessDevelopment
23
Achieved/AnticipatedMilestonesforAzurRxPotentialforMultipleCatalysts
Milestone Timing
InitiationofMS1819Phase2CPstudyinAustralia Q12017
Resultsfromfirst3patients in MS1819Phase2CPstudy Q22017
Resultsfromfirst6patientsinMS1819Phase2CPstudyshowingsafetyandefficacy>21%CFA Q32017
ProofofconceptdataforAZX1101 Q12018
CompletionofenrollmentinMS1819Phase2 CPstudy 1H2018
InitiationofMS1819Phase2CFstudy Mid2018
SubmitIND/CTAforMS1819 2H 2018
FinalresultsofMS1819Phase2CPstudy 2H2018
Initialresultsfrom CFstudy Q42018
24
IPO: 2016
Nasdaq: AZRX
Market Cap: $37MM(1)
Shares Outstanding: 11,554,146(2)
Cash Position (9/30/2017): $2.9MM
Locations: New York &Nîmes (France)
FinancialOverview
(1) As of 11/30/2017(2) As of 11/30/2017
25
§ Biotechnologycompanyfocusedonthedevelopmentoftherapeuticproteins
§MultiplepipelineprojectsaddressinglargeglobalmarketsinGIandinfectiousdiseases
§MS1819fortreatmentofExocrinePancreaticInsufficiency(EPI)inpatientswithChronicPancreatitis(CP)andCysticFibrosis(CF)
– ClinicalproofofconceptforCPdemonstratedinFLIP-110study
– PreliminaryPhase2datasupportsefficacyandsafetyinCP
– Large,immediatelyaddressableEPImarketof~$1BinU.S.,$1.5Bworldwide(1)
– PartneredwithMayoly-SpindlerinEuropecovering30%ofMS1819clinicalcosts
§AZX1101betalactamasesForpreventionofnosocomial(hospitalacquired)andC.difficileinfectionsinpreclinicaltesting
– Addressesa$4.5-$11billionmedicalissue(2)
§Highlycashefficientoperationswith~30%ofR&DspendrebatedbyFrenchgovernment
(1) U.S.marketsize.Abbvie 2013-201710-Ksandannualreports(Creon),Zenpep &Pancreaze basedon2013-2014IMShistoricaldata/analystprojection.ManagementestimatesforglobalEPImarketsize
(2) CDC2016 © AzurRx BioPharma < www.azurrx.com <
InvestmentHighlights
C O N F I D E N T I A L | www.azurrx.com
AdditionalCorporateInformationAppendix
27
§ Primaryefficacyendpoint
CFAchangefrombaselineandmeasuredattheendofPhaseConstandardizedhigh-fatmealsandstoolcollectionfor3days(dyemarker)
§ Secondaryefficacyendpoints
Keysecondaryendpoints- CFAchangefrombaselineandmeasuredatstep1-3ofPhaseC- Numberofdailyevacuations- ConsistencyofstoolsassessedbytheBristolscale
Othersecondaryendpoints- Bodyweightandbodymassindex- Weightofstoolsandabdominaldiscomfort- Absorptionvariables:nitrogenfecalcontentandsteatorrhea- Fastingglucose- Biochemistryandlipidparameters- Vitamins,Bone-turnovermarkers,andcirculatingnutritionproteins
MS1819CPPhase2a- PrimaryandSecondaryEfficacyEndpoints
28
§ Expectedclinicaladversereactionevents:– Allergicreaction– Hypoglycemia– Constipation– Abdominaldiscomfortorpain
§ Biologicalmarkers– Liver(AST,ALT)andmuscularenzymes(CK)– Renal(creatinemia,ureticacid)andpancreasmarkers(lipasemia,amylasemia)
§ SerumLIP2andanti-LIP2antibodies(ADA)detectionassays
§ Inaddition,laboratorytestswillinclude:– Fecalcalprotectinandfecalchymotrypsin– Hematology(completebloodcellcount),– Biochemistry(creatinine,urea,AST,ALT,ALP,GGT,bilirubin,andCK)– Serumvitamins,fastingglycaemia,lipidparameters,circulatingnutritionproteins,andbone-turnovermarkers.
MS1819CPPhase2a- SafetyEndpoints
29
0
250,000
500,000
750,000
1,000,000
1,250,000
1,500,000
1,750,000
2,000,000
2,250,000
2,500,000
2,750,000
3,000,000
3,250,000
3,500,000
3,750,000
4,000,000
0 4 8 12 16 20 24 28 32 36 40
EnzymaticActivy(TBU)ByPillBurden
Porcine- 00
35mgFD- 2
140mgFD- 2
212mgFD- 1
300mgFD- 0
400mgFD- 00
MS1819fillbycapsulesize
GreaterActivityEnablesDosingFlexibilityVariationsincapsulesizeallowallpatientstobedosedat1-2capsulespermeal
30
0
250,000
500,000
750,000
1,000,000
1,250,000
1,500,000
1,750,000
2,000,000
0 4 8 12 16 20 24 28 32 36 40
EnzymaticActivity(TBU)ByPillBurden
Creon
FD(4x)
Dailycapsuleburdenisproportionaltoenzymaticrequirements
1120mg/dayofMS1819
EnzymaticActivity(TB
UatpH6
)
Capsules
EnzymeRequirementsVary
Inamoderatepatient,theexpecteddailyminimumrequirementforenzymaticactivityisexpectedtobe1,000,000TBU
§ Moderatepatientscurrentlycontroldiseasetaking~25Creoncapsulestogive1,000,000TBU
§ Phase1wasdosedat250,000TBUgenerating~16%CFA
§ Phase2atestshigherdosescloserto1,000,000TBUwhichareexpectedtoprovideagreaterCFAresponse
Porcine
MS1819
DoseResponseThePhase1dailydoseofMS1819wasabout¼oftherequiredamountexpectedforamoderatepatient,higherdosesinphase2areexpectedtoachievebetterfatdigestion
31
BoardofDirectors
EdBorkowskiMr.Borkowski wastheCFOofConcordiaInternational andpreviouslyservedastheCFOofConvaTec Healthcare,CareFusionCorporationandMylan,Inc.andinavarietyoffinancepositionsatPharmacia,AmericanHomeProducts,CyanamidandatArthurAndersen.Mr.Borkowski holdsaBachelorofScienceinEconomicsandPoliticalSciencefromAlleghenyCollegeandaMasterinBusinessAdministrationinFinanceandAccountingfrom RutgersUniversity.
CharlesCasamentoMr.Casamento hasbeenexecutivedirectorandprincipalofTheSageGroup,ahealthcareadvisorygroup.HewaspresidentandCEOofOsteologix fromOctober2004untilApril2007,thefounder,president,chairmanandCEOofQuestcor Pharmaceuticals,andheldseniorleadershipandboardpositionsatRiboGene Inc,Indevus (formerlyInterneuronPharmaceuticals),GenzymeCorporation,Johnson&Johnson,Hoffmann-LaRoche andSandoz.Heholdsabachelor'sdegreeinPharmacyfromFordhamUniversityandanM.B.A.fromIonaCollegeandservesontheBoardsofDirectorsofInternationalStemCellCorporationandRelmada Therapeutics.
AlastairRiddell,MDDr.AlastairRiddelliscurrentlyChairmanofaprivateUKbiotech,NemesisBiosciencesLtd,ChairmanofaUKAIMlistedmedical imagingcompanyFeedbackplcandChairmanoftheSouthWestAcademicHealthScienceNetwork,andisalsoontheboardofdirectorsofSkyline VetPharma.Dr.Riddellhasover30yearsexperienceinthepharmaceutical,lifescienceandbiotechindustries,atLederle (nowPfizer),Centocor (nowJ&J),AmershamInternational(nowGEHealthcare)andasCEOofPharmagene,ParadigmTherapeuticsandStemCellSciences.Hebeganhiscareerasamedicaldoctor.
VernLeeSchramm,PhDDr.SchrammservedasChairmanoftheDepartmentofChemistryattheAlbertEinsteinCollegeofMedicinefrom1987to2015.Dr.SchrammwaselectedtotheNationalAcademyofSciencesin2007andwastheAssociateEditorforthe JournaloftheAmericanChemicalSociety from2003to2012.HehasbeenanadvisortoPicoPharmaceuticals,Metabalon Biochemistry,Sirtris Scientific,andBioCryst Pharmaceuticals.HeobtainedhisBSinBacteriologyfromSouthDakotaStateCollege,aMaster’sDegreeinNutritionbiochemistryfromHarvard,andaPh.D.fromAustralianNationalUniversity.
Maged ShenoudaMr.Shenouda waspreviouslytheHeadofBusinessDevelopmentandLicensingatRetrophin,Inc.Mr.Shenouda spentthebulkofhiscareerasanequityanalystatStifel Nicolaus,UBS,JPMorgan,CitigroupandBearStearnscoveringU.SandEuropeanpharmaceuticalcompanies.Mr.Shenouda wasamanagementconsultantwithPricewaterhouseCoopers,andamanagedcarespecialistforAbbottLaboratories.Mr.Shenouda earnedaB.S.inpharmacyfromSt.John'sUniversityanM.B.A.fromRutgersUniversityGraduateSchoolofManagement.
ThijsSpoorMr.SpoorwaspreviouslyPresidentandCEOofFluoropharma Medical,Inc.fromFebruary14,2011untilDecember31,2015. HewastheCFOforSunstoneBioSciences,astrategyconsultantatOliverWyman,anequityresearchanalystatJ.P.MorganandCreditSuissecoveringthebiotechnologyandmedicaldeviceindustries.Hespent11yearswithAmersham /GEHealthcareandholdsaPharmacydegreefromtheUniversityofTorontoaswellasanM.B.A.fromColumbiaUniversitywithconcentrationsinfinanceandaccounting.
32